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Association between Anemia Arising during Therapy and
Outcomes of Chemoradiation for Limited Small-cell
Lung Cancer
Scott A. Laurie, MD, FRCPC,* Neera Jeyabalan, MD, FRCPC,† Garth Nicholas, MD, FRCPC,*
Robert MacRae, MD, FRCPC,‡ and Simone Dahrouge, MSc*
Background: Anemia during chemoradiation is associated with
poorer outcomes in various cancers. Concurrent chemoradiation
(CCRT) is standard therapy for fit patients with limited small-cell
lung cancer (LD-SCLC). The objective of this study was to explore
the relationship between anemia and treatment outcomes in patients
with LD-SCLC treated with CCRT.
Methods: Charts of all patients with LD-SCLC receiving CCRT at
The Ottawa Hospital Regional Cancer Centre between January 1996
and December 2002 were reviewed. Information extracted included
demographics, known prognostic factors, treatment details, and
hemoglobin values from diagnosis until the completion of therapy.
Factors associated with outcomes were determined by Cox regres-
sion analyses.
Results: One hundred thirty patients were eligible for inclusion, and
their median survival was 18.1 months (95% CI, 14.8–25.1 months).
By univariate analysis, poorer outcome was associated with Eastern
Cooperative Oncology Group performance status 2, supraclavic-
ular adenopathy, and pre-radiotherapy hemoglobin 100 g/liter.
Pre-radiotherapy hemoglobin 100 g/liter was associated with both
an increased risk of progression (hazard ratio 1.8; P  0.04) and
death (hazard ratio 1.9; P  0.02) by multivariate analysis.
Conclusion: Anemia during CCRT for LD-SCLC is common and
may be associated with poorer outcome. Whether this association is
causative or simply prognostic is unclear, and it is not known
whether correction or prevention of anemia will improve outcome.
Clinical trials evaluating different target hemoglobin levels and the
roles of transfusion or erythropoietin during CCRT are needed.
Key Words: Small-cell lung cancer, Combined modality therapy,
Anemia, Predictive.
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Anemia is a common occurrence in cancer patients andmay arise for multiple reasons, including blood loss,
marrow infiltration, and treatment-induced myelosuppres-
sion. In retrospective analyses, the presence of anemia has
been associated with a poorer outcome with concurrent che-
moradiation (CCRT) in cancers of the head and neck,1 uterine
cervix,2 and non-small cell lung cancer.3 It is hypothesized
that the relationship between anemia and poor patient out-
come may be causal, in that anemia leads to decreased tumor
oxygenation, which in turn decreases radiosensitivity.
Small-cell histology accounts for 15 to 20% of all lung
cancers. Approximately 40% of patients with small-cell lung
cancer (SCLC) present with limited disease (LD), defined as
disease confined to one hemithorax and which can be encom-
passed in a single, tolerable radiotherapy portal. Most patients
in North America with LD-SCLC are treated for cure with
cisplatin-etoposide chemotherapy4 and receive thoracic radi-
ation with CCRT.5 In Canada, radiotherapy usually com-
mences with the second or third cycle of chemotherapy.6 The
addition of thoracic radiotherapy to chemotherapy increases
3-year survival by approximately 5%.7,8
There are limited data regarding the relationship be-
tween anemia and outcomes of therapy in SCLC. There are
conflicting reports regarding the impact on survival of base-
line anemia before the commencement of any therapy in
patients with LD-SCLC,9–11 but none on the impact of the
development of anemia during therapy. This exploratory
analysis was undertaken to examine the influence of anemia
arising during CCRT for LD-SCLC.
METHODS
Patients and Information Extracted from the
Medical Record
The Ottawa Hospital Regional Cancer Centre (ORCC)
is a comprehensive academic cancer treatment facility that
serves as the only provider of oncologic care for a population
of 1.2 million. After approval by the research ethics board of
The Ottawa Hospital, the database of the ORCC was searched
to retrieve the charts of all patients with a diagnosis of
LD-SCLC registered at the ORCC between January 1, 1996
and December 31, 2002 who were treated with curative-intent
CCRT. To be eligible for inclusion in this review, patients
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must have received all therapy for this malignancy at the
ORCC. Those few who commenced or received their initial
treatment elsewhere and were referred for ongoing care,
treatment of relapsed disease, or solely for follow-up, were
excluded. All patients who had an intended treatment plan of
CCRT were included regardless of whether they completed
the intended course of therapy. Patients treated with sequen-
tial chemoradiation were not included. Pathologic confirma-
tion of pure SCLC was required; mixed small-cell and non-
small cell histologies were excluded. All included patients
had adequate staging investigations to confirm LD (comput-
erized tomography scans of the head and chest; bone scan;
and abdominal imaging, either computerized tomography or
ultrasound). Patients with cytologically unsampled pleural
effusions and those with ipsilateral supraclavicular lymph
nodes were included if they were treated as LD-SCLC.
During the period of the study, standard practice at the
ORCC with respect to chemotherapy was a planned admin-
istration of six cycles of cisplatin-etoposide unless a specific
contraindication precluded this regimen. The commonly pre-
scribed dose of thoracic radiotherapy evolved over the time
interval, from 40 Gy in 15 fractions for those treated earlier
in the period, to 50 Gy in 25 fractions for those treated more
recently. Prophylactic cranial irradiation (PCI) became rou-
tine for those with a complete remission after the publication
of the 1999 meta-analysis.12 After completion of therapy,
patients were generally seen at 2-month intervals, with rou-
tine blood work and chest x-rays at each visit, with additional
investigations directed by results of these tests and patient
symptoms.
The following baseline pretreatment demographic and
prognostic information was extracted: age; sex; Eastern Co-
operative Oncology Group (ECOG) performance status (PS);
weight loss; smoking history (active, ex-smoker, never);
presence of mediastinal lymphadenopathy; ipsilateral pleural
effusion or ipsilateral supraclavicular lymphadenopathy; and
serum sodium, alkaline phosphatase, and lactate dehydroge-
nase (LDH) levels. Treatment details extracted were the
chemotherapy regimen and number of cycles delivered, as
well as the dose of radiation and the cycle of chemotherapy
with which radiation commenced. All available hemoglobin
data were recorded, from diagnosis until the completion of
the CCRT, and details of any transfusions for anemia or use
of erythropoietin were documented.
Statistical Analyses
Outcome intervals were calculated from the date of
initiation of therapy to the date of death for overall survival,
and the date of first radiographic or clinical evidence of
progression or death for progression-free survival. Survival
duration for patients who were alive without progression was
censored on the date of last follow-up.
The objective of this retrospective review was to eval-
uate whether there may be a relationship between hemoglobin
levels before or during CCRT for LD-SCLC, and overall and
progression-free survival. Multiple hemoglobin parameters
were evaluated in this exploratory analysis, based on what
has been determined to be significant for other malignan-
cies.1–3,13,14 These were baseline hemoglobin before the ini-
tiation of any therapy; pre-radiotherapy hemoglobin (after
chemotherapy alone and immediately before the commence-
ment of radiation concurrent with additional cycles of che-
motherapy); and nadir hemoglobin documented during radi-
ation. These values were examined both as continuous and
categorical variables, with the following categories used:
normal versus abnormal (115 g/liter for women and 135
g/liter for men); 120 g/liter; and 100 g/liter.
The data were analyzed using the statistical package
SAS version 8.0 (SAS Institute, Cary, NC). Kaplan-Meier
plots were used to estimate overall and progression-free
survival.15 The effect of single variables on overall and
progression-free survival was assessed with the log-rank test
and with Kaplan-Meier plots. Cox multivariable regression
analyses16 were used to evaluate the effect of the various
hemoglobin parameters on survival in the presence of poten-
tial confounding factors including age, weight loss, sex, PS,
smoking status, presence of mediastinal and/or supraclavic-
ular nodes, presence of a pleural effusion, serum sodium and
alkaline phosphatase levels, chemotherapy regimen used, and
dose and timing of thoracic radiotherapy. Hemoglobin vari-
ables associated with particular dates (such as pre-radiother-
apy hemoglobin) were analyzed as time-varying covariates,
entering the analysis only after the dates they had occurred.
Baseline LDH data were available only in a subset of patients
(n  37); therefore, this was excluded from the analyses to
avoid case-wise deletions.
RESULTS
Patient Characteristics and Survival
The database identified 137 patients with a new diag-
nosis of LD-SCLC over the study time period for whom the
intended treatment plan was CCRT. Of these, two patients
were excluded because they had been referred only for
follow-up or relapse of LD-SCLC treated elsewhere. An
additional five patients refused all therapy for their malig-
nancy and were lost to follow-up. Thus, a total of 130 patients
with an intended treatment plan of CCRT fulfilled the eligi-
bility criteria and were analyzable for the effects of baseline
hemoglobin levels. These patients had the usual characteris-
tics of those with SCLC (Table 1), except for a higher
proportion of those with untapped ipsilateral pleural effusions
(21% of patients). Most received platinum-based chemother-
apy, either cisplatin-etoposide (85%) or carboplatin-etopo-
side (12 %), and most received six cycles.
Seven patients died or progressed after initiation of
chemotherapy but before the initiation of any radiation,
leaving 123 patients who received at least one fraction of
radiotherapy and who were therefore included in the analysis
for the relationship between hemoglobin levels during the
concurrent chemoradiation portion of therapy. Compared
with the other patients, these seven patients did not differ
significantly in terms of their median baseline hemoglobin
levels. The median dose of radiotherapy delivered was 50 Gy
(range, 5-60 Gy). Most patients received either 40 Gy in 15
fractions (33% of patients) or 50 Gy in 25 fractions (48% of
patients). Radiotherapy was administered “early”, defined as
commencing with or before cycle 3 of chemotherapy, in 66%
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of patients, and radiotherapy commenced concurrently with
cycle 4 in an additional 21%. PCI was administered to 56%
of patients. Radiotherapy was halted prematurely in five
patients because of toxicity, and in one patient who refused
further therapy after receiving two fractions of radiation.
There were no deaths during the CCRT portion of treatment.
The median overall and progression-free survivals for
all 130 patients were 18.1 (95% CI, 14.8–25.1 months) and
11.7 months (95% CI, 9.4–14.2 months), respectively. Five-
year overall survival was 15.6%.
Hemoglobin Parameters
As expected, median hemoglobin levels decrease dur-
ing therapy and recover after completion of therapy (Figure
1). The median baseline hemoglobin before any treatment
was 135 g/liter (range, 85–89). The median pre-radiotherapy
hemoglobin level was 116 g/liter (range, 85–152), and me-
dian nadir hemoglobin during radiotherapy was 101 g/liter
(range, 69–138). The proportion of patients with pre-radio-
therapy hemoglobin 100 g/liter increased with increasing
delay in the onset of concurrent radiotherapy. When radio-
therapy commenced within the first two cycles of chemother-
apy, only 4% of patients had hemoglobin levels 100 g/liter
at the initiation of radiation. Among patients for whom
radiotherapy commenced later, 26% had a pre-radiotherapy
hemoglobin level 100 g/liter. Overall, 19 patients had
pre-radiotherapy hemoglobin 100 g/liter, whereas a total of
53 (including these 19) had nadir hemoglobin 100 g/liter
during radiotherapy.
Transfusions were given to 43% of patients. The me-
dian threshold level of hemoglobin to trigger a transfusion
was 84 g/liter. Seven patients were enrolled on a double-blind
phase III clinical trial of erythropoietin or placebo added to
standard CCRT and therefore may have received erythropoi-
etin; routine use of erythropoietin did not otherwise occur.
Univariate Analysis
The following baseline factors were associated with the
both the risk of progression and death in the univariate
analysis in both the entire cohort (n  130) and in the cohort
of 123 patients who received radiation: ECOG PS2 and the
presence of supraclavicular lymph nodes. In the cohort that
received any concurrent radiation, pre-radiotherapy hemoglo-
bin 100 g/liter was also predictive. Receipt of PCI was
predictive of improved overall survival; however, to avoid
potential bias (patients who completed CCRT with a good
response would be more likely to receive PCI), this was not
included in the multivariate model. Age, sex, smoking status,
serum sodium, chemotherapy regimen used, dose and timing
of radiotherapy, and presence of ipsilateral pleural effusion,
mediastinal lymphadenopathy, or pre-treatment weight loss
were not statistically predictive of outcome, nor were any of
the other hemoglobin parameters examined, although the
association with outcome was usually in the direction ex-
pected.
Multivariate Analysis
Models were built for the prediction of overall survival
and progression-free survival separately. For the whole pop-
ulation of 130 patients, performance status 2 (hazard ratio
[HR] 2.5; P  0.01) and the presence of supraclavicular
nodes (HR 2.1; P  0.03) were independently predictive of
overall survival. Pre-treatment baseline hemoglobin was not
an independent predictor of either progression or death. In the
subset of 123 patients who received any radiotherapy con-
current with chemotherapy, by multivariate analysis, pre-
radiotherapy hemoglobin 100 g/liter was independently
associated with worse progression-free (HR 1.8; P  0.04)
TABLE 1. Patient Characteristics
Characteristics n  130 (%)
Median age (years) 62 (range, 43 – 87)
Gender
Male 63 (48)
Female 67 (52)
ECOG performance status before Rx
0–1 117 (93)
2 13 (7)
Weight loss before Rx 51 (43)
Smoking Status:
Ex-smoker 81 (66)
Active smoker 38 (31)
Non-smoker 3 (3)
Median labs
Sodium (mmol/liter) 139 (range, 115-147)
LDH (IU/liter) 275 (range, 128-2515)
Presence of
Supraclavicular nodes 11 (8)
Pleural effusion 27 (21)
Chemotherapy
Cisplatin/etoposide 110 (85)
Carboplatin/etoposide 15 (12)
Other 5 (4)
Radiation
Median dose delivered (Gy) 50 (range, 5-60)
XRT with or before third cycle chemo 81 (66)
ECOG, Eastern Cooperative Oncology Group; Rx, therapy; LDH, lactate dehydro-
genase; XRT, thoracic radiotherapy.
FIGURE 1. Hemoglobin changes during therapy. Each dia-
mond represents a hemoglobin value for a patient in the cur-
rent cohort.
Laurie et al. Journal of Thoracic Oncology • Volume 1, Number 2, February 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer148
and overall survival rates (HR 1.9; P  0.02). There was a
trend that this variable was also associated with a higher risk
of progression within the radiated field (HR 2.5; P  0.07).
The median overall survival for patients with pre-radiother-
apy hemoglobin 100 g/liter was 22.6 months, compared
with 13.1 months for those with pre-radiotherapy hemoglobin
100 g/liter (log rank; P  0.034) (Figure 2). When the
analysis was repeated to include the receipt of PCI in the
model, pre-radiotherapy hemoglobin 100 g/liter remained
independently associated with overall survival (HR 1.7; P 
0.05).
DISCUSSION
Anemia is a common occurrence in patients treated
with CCRT for LD-SCLC, resulting in transfusions in 43% of
patients in this series. The etiology of the anemia is multi-
factorial, but treatment is clearly a major contributor. This
analysis suggests that hemoglobin 100 g/liter at the initia-
tion of radiotherapy is associated with a poorer outcome.
Other baseline clinical factors previously shown to be prog-
nostic for SCLC were also predictive in this cohort, and the
median survival was comparable to that obtained in clinical
trials in LD-SCLC. This implies that the characteristics of
these patients are representative of those of the general
population with LD-SCLC treated with CCRT. This supports
the possibility that the relationship between hemoglobin and
outcome is a true finding. However, definitive conclusions
cannot be drawn, as this review is limited by its retrospective
nature and missing data, particularly the high proportion of
patients without baseline LDH levels. There was also signif-
icant heterogeneity in the treatment given to the patients
within the cohort. As the analysis was exploratory, the testing
of multiple hemoglobin parameters increases the likelihood
of detecting a relationship solely by chance.
Any potential association between anemia and outcome
in any malignancy is not necessarily causative. Cancers
secreting cytokines that lead to anemia of chronic disease
may be intrinsically more resistant to therapy. Whether
present at baseline or arising during therapy, anemia may
reflect undetected bone marrow metastases. A bone marrow
aspirate was not performed in any patient in this cohort, nor
was it required in the work-up of patients enrolled into the
clinical trial that determined baseline hemoglobin to be pre-
dictive of survival in LD-SCLC.17 Anemia may simply be
another marker of the burden of disease, much like LDH.
The impact, if any, of anemia on treatment might vary
with the underlying malignancy. A greater negative effect on
outcome could be expected when the major modality of
curative therapy is radiation, as is the case in squamous cell
carcinoma of the head and neck or uterine cervix. In contrast,
chemotherapy is the primary modality of treatment of SCLC,
with adjunctive radiation contributing to a significant, but
modest, improvement in survival.7,8 There was a trend toward
poorer local control in the cohort of patients with pre-
radiotherapy hemoglobin 100 g/liter. However, the magni-
tude of the difference in median survival observed in the
current series between those patients with pre-radiotherapy
hemoglobin 100 g/liter or 100 g/liter suggests that radio-
resistance as a result of anemia is not likely the sole expla-
nation. Although preclinical data suggest that hypoxia is
associated with chemoresistance,18 no clinical data are avail-
able regarding the independent effect of anemia on the
chemotherapy of malignancies such as testicular cancer,
SCLC, or lymphoma.
If the association between pre-radiotherapy hemoglo-
bin 100 g/liter and a poorer outcome is causative, does this
arise because of increased chemoresistance, radioresistance,
or both? Patients in this cohort generally became progres-
sively more anemic during the course of their treatment, and
the proportion of patients with pre-radiotherapy hemoglobin
100 g/liter increased as the concurrent radiotherapy com-
menced with later cycles of chemotherapy. In this small
cohort, no effect of timing of radiotherapy could be detected,
but this raises the possibility that the benefit of “early” versus
“late” radiotherapy observed in clinical trials6,19 might be, in
part, the result of a greater incidence of anemia in those
receiving late radiotherapy. Alternatively, the negative im-
pact could be more indirect, from poor treatment tolerance
and impaired treatment delivery in the anemic patient, result-
ing in less than optimal therapy. As few patients failed to
complete CCRT once radiotherapy was commenced, no dif-
ference can be detected in the current study in the rates of
completion of therapy between the two groups or in the
median dose of radiotherapy delivered. Information regarding
dose adjustments and delays in chemotherapy was not col-
lected.
There is much interest in determining whether relieving
or preventing anemia improves results of therapy for malig-
nancies and, if so, how best to accomplish this. There is
retrospective evidence that correction of anemia through
blood transfusion in patients with cervical cancer leads to
results with radiation comparable to those in patients who do
not become anemic during therapy, whereas those who re-
main anemic have a poorer outcome.13 However, randomized
trials comparing higher versus lower target hemoglobin levels
in patients undergoing radiotherapy for cervical cancer20 or
squamous cell carcinoma of the head and neck21 did not
FIGURE 2. Overall survival by cohort of pre-radiotherapy
hemoglobin.
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detect significant improvements in outcomes in the cohorts
randomized to maintain a higher hemoglobin level. Use of
erythropoietin can correct anemia arising during chemother-
apy, and in the palliative setting, this is associated with
improvements in quality of life.22–24 However, its routine use
in the curative setting must be approached with caution. One
reported trial, in which patients with locally advanced squa-
mous cell carcinoma of the head and neck were randomized
to receive subcutaneous erythropoietin or placebo during
their definitive radiotherapy, found that despite a higher mean
hemoglobin level in the erythropoietin group, the use of
erythropoietin was associated with a poorer outcome.25 In this
study, pre-treatment anemia and anemia during radiation both
had an association with a poorer survival, but despite this,
correction with erythropoietin was detrimental. There is,
however, some controversy regarding interpretation of these
results, because of some methodological concerns. A second,
similar, randomized trial conducted by the Radiation Therapy
Oncology Group (protocol 99-03) likewise showed no benefit
to the addition of erythropoietin to definitive radiation for
cancer of the head and neck.26 Another randomized clinical
trial of the role of erythropoietin added to standard CCRT for
LD-SCLC was halted prematurely because of a higher rate of
serious thrombotic events in the erythropoietin arm.27 It is
possible that target hemoglobin levels should be lower to
prevent an increase in blood viscosity that predisposes pa-
tients to thrombotic events and that also likely impairs tumor
blood flow,28 thus negating any improvement in oxygen
delivery that correction of anemia would allow. One mathe-
matical model of tumor blood flow suggests that tumor
oxygen delivery peaks at a hemoglobin concentration of 110
g/liter and that a significant decrease in oxygenation only
occurs at hemoglobin levels 80 g/liter.28 Certainly, patients
who develop profound and/or symptomatic anemia should
receive blood transfusions as good clinical practice to relieve
symptoms and possibly improve tolerance of therapy, but
complete correction of hemoglobin to normal levels during
treatment may be neither necessary nor desired, and the
routine use of erythropoietin during CCRT should be ap-
proached with caution.
The finding that a hemoglobin level 100 g/liter im-
mediately before the initiation of CCRT for LD-SCLC is
associated with a poorer outcome is intriguing but can serve
only to generate hypotheses for further evaluation and re-
quires confirmation in a larger cohort of homogeneously
treated patients. Even if such an association exists, it does not
necessarily follow that correction of anemia will be benefi-
cial. Prospective clinical trials examining different target
hemoglobin levels and comparing blood transfusion to eryth-
ropoietin are needed in malignancies in which a strong and
consistent association between hemoglobin and outcome of
therapy has been demonstrated.
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